1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Cystic Fibrosis Market
2.2. Global Cystic Fibrosis Market, By Drug Class, 2023 (US$ Million)
2.3. Global Cystic Fibrosis Market, By Route Of Administration, 2023 (US$ Million)
2.4. Global Cystic Fibrosis Market, By Distribution Channel, 2023 (US$ Million)
2.5. Global Cystic Fibrosis Market, By Geography, 2023 (US$ Million)
2.6. Attractive Investment Proposition by Geography, 2023

3. Cystic Fibrosis Market: Competitive Analysis
3.1. Market Positioning of Key Cystic Fibrosis Market Vendors
3.2. Strategies Adopted by Cystic Fibrosis Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2023 Versus 2032

4. Cystic Fibrosis Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Cystic Fibrosis Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Pancreatic Enzyme Supplements
5.3.2. Mucolytic
5.3.3. Bronchodilators
5.3.4. CFTR modulators
5.3.5. Others

6. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Oral
6.3.2. Inhaled

7. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Growth & Revenue Analysis: 2023 Versus 2032
7.3. Market Segmentation
7.3.1. Retail Pharmacies & Drug Stores
7.3.2. Online Pharmacies
7.3.3. Hospital Pharmacies


8. North America Cystic Fibrosis Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
8.3. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
8.4. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
8.5.Cystic Fibrosis Market: By Region, 2022-2032, USD (Million)
8.5.1.North America
8.5.1.1. U.S.
8.5.1.1.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
8.5.1.1.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
8.5.1.1.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
8.5.1.2. Canada
8.5.1.2.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
8.5.1.2.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
8.5.1.2.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
8.5.1.3. Rest of North America
8.5.1.3.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
8.5.1.3.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
8.5.1.3.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)

9. UK and European Union Cystic Fibrosis Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
9.3. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
9.4. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
9.5.Cystic Fibrosis Market: By Region, 2022-2032, USD (Million)
9.5.1.UK and European Union
9.5.1.1. UK
9.5.1.1.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
9.5.1.1.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
9.5.1.1.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
9.5.1.2. Germany
9.5.1.2.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
9.5.1.2.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
9.5.1.2.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
9.5.1.3. Spain
9.5.1.3.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
9.5.1.3.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
9.5.1.3.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
9.5.1.4. Italy
9.5.1.4.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
9.5.1.4.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
9.5.1.4.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
9.5.1.5. France
9.5.1.5.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
9.5.1.5.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
9.5.1.5.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
9.5.1.6. Rest of Europe
9.5.1.6.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
9.5.1.6.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
9.5.1.6.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)

10. Asia Pacific Cystic Fibrosis Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
10.3. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
10.4. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
10.5.Cystic Fibrosis Market: By Region, 2022-2032, USD (Million)
10.5.1.Asia Pacific
10.5.1.1. China
10.5.1.1.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
10.5.1.1.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
10.5.1.1.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
10.5.1.2. Japan
10.5.1.2.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
10.5.1.2.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
10.5.1.2.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
10.5.1.3. India
10.5.1.3.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
10.5.1.3.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
10.5.1.3.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
10.5.1.4. Australia
10.5.1.4.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
10.5.1.4.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
10.5.1.4.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
10.5.1.5. South Korea
10.5.1.5.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
10.5.1.5.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
10.5.1.5.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
10.5.1.6. Rest of Asia Pacific
10.5.1.6.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
10.5.1.6.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
10.5.1.6.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)

11. Latin America Cystic Fibrosis Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
11.3. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
11.4. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
11.5.Cystic Fibrosis Market: By Region, 2022-2032, USD (Million)
11.5.1.Latin America
11.5.1.1. Brazil
11.5.1.1.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
11.5.1.1.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
11.5.1.1.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
11.5.1.2. Mexico
11.5.1.2.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
11.5.1.2.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
11.5.1.2.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
11.5.1.3. Rest of Latin America
11.5.1.3.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
11.5.1.3.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
11.5.1.3.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)

12. Middle East and Africa Cystic Fibrosis Market, 2022-2032, USD (Million)
12.1. Market Overview
12.2. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
12.3. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
12.4. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
12.5.Cystic Fibrosis Market: By Region, 2022-2032, USD (Million)
12.5.1.Middle East and Africa
12.5.1.1. GCC
12.5.1.1.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
12.5.1.1.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
12.5.1.1.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
12.5.1.2. Africa
12.5.1.2.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
12.5.1.2.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
12.5.1.2.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)
12.5.1.3. Rest of Middle East and Africa
12.5.1.3.1. Cystic Fibrosis Market: By Drug Class, 2022-2032, USD (Million)
12.5.1.3.2. Cystic Fibrosis Market: By Route Of Administration, 2022-2032, USD (Million)
12.5.1.3.3. Cystic Fibrosis Market: By Distribution Channel, 2022-2032, USD (Million)

13. Company Profile
13.1. 4D Molecular Therapeutics Inc.
13.1.1. Company Overview
13.1.2. Financial Performance
13.1.3. Product Portfolio
13.1.4. Strategic Initiatives
13.2. AbbVie Inc
13.2.1. Company Overview
13.2.2. Financial Performance
13.2.3. Product Portfolio
13.2.4. Strategic Initiatives
13.3. Abeona Therapeutics Inc
13.3.1. Company Overview
13.3.2. Financial Performance
13.3.3. Product Portfolio
13.3.4. Strategic Initiatives
13.4. Affinia Therapeutics
13.4.1. Company Overview
13.4.2. Financial Performance
13.4.3. Product Portfolio
13.4.4. Strategic Initiatives
13.5. Agile Sciences Inc
13.5.1. Company Overview
13.5.2. Financial Performance
13.5.3. Product Portfolio
13.5.4. Strategic Initiatives
13.6. AGILeBiotics BV
13.6.1. Company Overview
13.6.2. Financial Performance
13.6.3. Product Portfolio
13.6.4. Strategic Initiatives
13.7. Airbase Breathing Co LLC
13.7.1. Company Overview
13.7.2. Financial Performance
13.7.3. Product Portfolio
13.7.4. Strategic Initiatives
13.8. Airway Therapeutics LLC
13.8.1. Company Overview
13.8.2. Financial Performance
13.8.3. Product Portfolio
13.8.4. Strategic Initiatives
13.9. Alaxia SAS
13.9.1. Company Overview
13.9.2. Financial Performance
13.9.3. Product Portfolio
13.9.4. Strategic Initiatives
13.10. AlgiPharma AS
13.10.1. Company Overview
13.10.2. Financial Performance
13.10.3. Product Portfolio
13.10.4. Strategic Initiatives
13.11. Altavant Sciences Inc
13.11.1. Company Overview
13.11.2. Financial Performance
13.11.3. Product Portfolio
13.11.4. Strategic Initiatives
13.12. Amgen Inc
13.12.1. Company Overview
13.12.2. Financial Performance
13.12.3. Product Portfolio
13.12.4. Strategic Initiatives
13.13. Antabio SAS
13.13.1. Company Overview
13.13.2. Financial Performance
13.13.3. Product Portfolio
13.13.4. Strategic Initiatives
13.14. Arch Biopartners Inc
13.14.1. Company Overview
13.14.2. Financial Performance
13.14.3. Product Portfolio
13.14.4. Strategic Initiatives
13.15. Arcturus Therapeutics Ltd
13.15.1. Company Overview
13.15.2. Financial Performance
13.15.3. Product Portfolio
13.15.4. Strategic Initiatives
13.16. Armata Pharmaceuticals
13.16.1. Company Overview
13.16.2. Financial Performance
13.16.3. Product Portfolio
13.16.4. Strategic Initiatives
13.17. Arrevus Inc
13.17.1. Company Overview
13.17.2. Financial Performance
13.17.3. Product Portfolio
13.17.4. Strategic Initiatives
13.18. Arrowhead Pharmaceuticals Inc
13.18.1. Company Overview
13.18.2. Financial Performance
13.18.3. Product Portfolio
13.18.4. Strategic Initiatives
13.19. AstraZeneca Plc
13.19.1. Company Overview
13.19.2. Financial Performance
13.19.3. Product Portfolio
13.19.4. Strategic Initiatives
13.20. Atlantic Healthcare Plc
13.20.1. Company Overview
13.20.2. Financial Performance
13.20.3. Product Portfolio
13.20.4. Strategic Initiatives
13.21. Avidin Biotechnology Ltd
13.21.1. Company Overview
13.21.2. Financial Performance
13.21.3. Product Portfolio
13.21.4. Strategic Initiatives
13.22. BioAegis Therapeutics Inc
13.22.1. Company Overview
13.22.2. Financial Performance
13.22.3. Product Portfolio
13.22.4. Strategic Initiatives
13.23. Biofilm Pharma
13.23.1. Company Overview
13.23.2. Financial Performance
13.23.3. Product Portfolio
13.23.4. Strategic Initiatives
13.24. Biolytx Pharmaceuticals Corp
13.24.1. Company Overview
13.24.2. Financial Performance
13.24.3. Product Portfolio
13.24.4. Strategic Initiatives
13.25. Boehringer Ingelheim International GmbH
13.25.1. Company Overview
13.25.2. Financial Performance
13.25.3. Product Portfolio
13.25.4. Strategic Initiatives
13.26. Boston Pharmaceuticals Inc
13.26.1. Company Overview
13.26.2. Financial Performance
13.26.3. Product Portfolio
13.26.4. Strategic Initiatives
13.27. Breathe Easy Therapeutics Ltd
13.27.1. Company Overview
13.27.2. Financial Performance
13.27.3. Product Portfolio
13.27.4. Strategic Initiatives
13.28. BridgeBio Pharma Inc
13.28.1. Company Overview
13.28.2. Financial Performance
13.28.3. Product Portfolio
13.28.4. Strategic Initiatives
13.29. Calista Therapeutics Inc
13.29.1. Company Overview
13.29.2. Financial Performance
13.29.3. Product Portfolio
13.29.4. Strategic Initiatives
13.30. Calithera Biosciences Inc
13.30.1. Company Overview
13.30.2. Financial Performance
13.30.3. Product Portfolio
13.30.4. Strategic Initiatives
13.31. Catabasis Pharmaceuticals Inc
13.31.1. Company Overview
13.31.2. Financial Performance
13.31.3. Product Portfolio
13.31.4. Strategic Initiatives
13.32. Celtaxsys Inc
13.32.1. Company Overview
13.32.2. Financial Performance
13.32.3. Product Portfolio
13.32.4. Strategic Initiatives
13.33. Chiesi Farmaceutici SpA
13.33.1. Company Overview
13.33.2. Financial Performance
13.33.3. Product Portfolio
13.33.4. Strategic Initiatives
13.34. Chrysalis Pharma SAS
13.34.1. Company Overview
13.34.2. Financial Performance
13.34.3. Product Portfolio
13.34.4. Strategic Initiatives
13.35. Cilian AG
13.35.1. Company Overview
13.35.2. Financial Performance
13.35.3. Product Portfolio
13.35.4. Strategic Initiatives
13.36. ContraFect Corp
13.36.1. Company Overview
13.36.2. Financial Performance
13.36.3. Product Portfolio
13.36.4. Strategic Initiatives
13.37. Copernicus Therapeutics Inc
13.37.1. Company Overview
13.37.2. Financial Performance
13.37.3. Product Portfolio
13.37.4. Strategic Initiatives
13.38. Corbus Pharmaceuticals Inc
13.38.1. Company Overview
13.38.2. Financial Performance
13.38.3. Product Portfolio
13.38.4. Strategic Initiatives
13.39. CRISPR Therapeutics AG
13.39.1. Company Overview
13.39.2. Financial Performance
13.39.3. Product Portfolio
13.39.4. Strategic Initiatives
13.40. CrowdOut Therapeutics
13.40.1. Company Overview
13.40.2. Financial Performance
13.40.3. Product Portfolio
13.40.4. Strategic Initiatives
13.41. CSA Biotechnologies LLC
13.41.1. Company Overview
13.41.2. Financial Performance
13.41.3. Product Portfolio
13.41.4. Strategic Initiatives
13.42. Cyclacel Pharmaceuticals Inc
13.42.1. Company Overview
13.42.2. Financial Performance
13.42.3. Product Portfolio
13.42.4. Strategic Initiatives
13.43. Cyclenium Pharma Inc
13.43.1. Company Overview
13.43.2. Financial Performance
13.43.3. Product Portfolio
13.43.4. Strategic Initiatives
13.44. Daiichi Sankyo Co Ltd
13.44.1. Company Overview
13.44.2. Financial Performance
13.44.3. Product Portfolio
13.44.4. Strategic Initiatives
13.45. Destiny Pharma Plc
13.45.1. Company Overview
13.45.2. Financial Performance
13.45.3. Product Portfolio
13.45.4. Strategic Initiatives
13.46. DiscoveryBiomed Inc
13.46.1. Company Overview
13.46.2. Financial Performance
13.46.3. Product Portfolio
13.46.4. Strategic Initiatives
13.47. Editas Medicine Inc
13.47.1. Company Overview
13.47.2. Financial Performance
13.47.3. Product Portfolio
13.47.4. Strategic Initiatives
13.48. Eloxx Pharmaceuticals Inc
13.48.1. Company Overview
13.48.2. Financial Performance
13.48.3. Product Portfolio
13.48.4. Strategic Initiatives
13.49. EmphyCorp Inc
13.49.1. Company Overview
13.49.2. Financial Performance
13.49.3. Product Portfolio
13.49.4. Strategic Initiatives
13.50. EnBiotix Inc
13.50.1. Company Overview
13.50.2. Financial Performance
13.50.3. Product Portfolio
13.50.4. Strategic Initiatives
13.51. enGene Inc
13.51.1. Company Overview
13.51.2. Financial Performance
13.51.3. Product Portfolio
13.51.4. Strategic Initiatives
13.52. Enterprise Therapeutics Ltd
13.52.1. Company Overview
13.52.2. Financial Performance
13.52.3. Product Portfolio
13.52.4. Strategic Initiatives
13.53. Entrinsic Bioscience Inc
13.53.1. Company Overview
13.53.2. Financial Performance
13.53.3. Product Portfolio
13.53.4. Strategic Initiatives
13.54. Enzyvant Sciences Ltd
13.54.1. Company Overview
13.54.2. Financial Performance
13.54.3. Product Portfolio
13.54.4. Strategic Initiatives
13.55. Errant Gene Therapeutics LLC
13.55.1. Company Overview
13.55.2. Financial Performance
13.55.3. Product Portfolio
13.55.4. Strategic Initiatives
13.56. Evaxion Biotech ApS
13.56.1. Company Overview
13.56.2. Financial Performance
13.56.3. Product Portfolio
13.56.4. Strategic Initiatives
13.57. Evotec SE
13.57.1. Company Overview
13.57.2. Financial Performance
13.57.3. Product Portfolio
13.57.4. Strategic Initiatives
13.58. Exotect LLC
13.58.1. Company Overview
13.58.2. Financial Performance
13.58.3. Product Portfolio
13.58.4. Strategic Initiatives
13.59. F. Hoffmann-La Roche Ltd
13.59.1. Company Overview
13.59.2. Financial Performance
13.59.3. Product Portfolio
13.59.4. Strategic Initiatives
13.60. Feldan Therapeutics Inc
13.60.1. Company Overview
13.60.2. Financial Performance
13.60.3. Product Portfolio
13.60.4. Strategic Initiatives
13.61. Galapagos NV
13.61.1. Company Overview
13.61.2. Financial Performance
13.61.3. Product Portfolio
13.61.4. Strategic Initiatives
13.62. Galenus Therapeutics Inc
13.62.1. Company Overview
13.62.2. Financial Performance
13.62.3. Product Portfolio
13.62.4. Strategic Initiatives
13.63. Generation Bio Co
13.63.1. Company Overview
13.63.2. Financial Performance
13.63.3. Product Portfolio
13.63.4. Strategic Initiatives
13.64. Genzyme Corp
13.64.1. Company Overview
13.64.2. Financial Performance
13.64.3. Product Portfolio
13.64.4. Strategic Initiatives
13.65. Helperby Therapeutics Group Ltd
13.65.1. Company Overview
13.65.2. Financial Performance
13.65.3. Product Portfolio
13.65.4. Strategic Initiatives
13.66. Horizon Therapeutics Plc
13.66.1. Company Overview
13.66.2. Financial Performance
13.66.3. Product Portfolio
13.66.4. Strategic Initiatives
13.67. Icagen Inc
13.67.1. Company Overview
13.67.2. Financial Performance
13.67.3. Product Portfolio
13.67.4. Strategic Initiatives
13.68. Idorsia Pharmaceutical Ltd
13.68.1. Company Overview
13.68.2. Financial Performance
13.68.3. Product Portfolio
13.68.4. Strategic Initiatives
13.69. Immun System IMS AB
13.69.1. Company Overview
13.69.2. Financial Performance
13.69.3. Product Portfolio
13.69.4. Strategic Initiatives
13.70. Insmed Inc
13.70.1. Company Overview
13.70.2. Financial Performance
13.70.3. Product Portfolio
13.70.4. Strategic Initiatives
13.71. Invion Ltd
13.71.1. Company Overview
13.71.2. Financial Performance
13.71.3. Product Portfolio
13.71.4. Strategic Initiatives
13.72. Ionis Pharmaceuticals Inc
13.72.1. Company Overview
13.72.2. Financial Performance
13.72.3. Product Portfolio
13.72.4. Strategic Initiatives
13.73. Kamada Ltd
13.73.1. Company Overview
13.73.2. Financial Performance
13.73.3. Product Portfolio
13.73.4. Strategic Initiatives
13.74. Kither Biotech Srl
13.74.1. Company Overview
13.74.2. Financial Performance
13.74.3. Product Portfolio
13.74.4. Strategic Initiatives
13.75. Krystal Biotech Inc
13.75.1. Company Overview
13.75.2. Financial Performance
13.75.3. Product Portfolio
13.75.4. Strategic Initiatives
13.76. Lakewood-Amedex Inc
13.76.1. Company Overview
13.76.2. Financial Performance
13.76.3. Product Portfolio
13.76.4. Strategic Initiatives
13.77. Lamellar Biomedical Ltd
13.77.1. Company Overview
13.77.2. Financial Performance
13.77.3. Product Portfolio
13.77.4. Strategic Initiatives
13.78. Laurel Therapeutics
13.78.1. Company Overview
13.78.2. Financial Performance
13.78.3. Product Portfolio
13.78.4. Strategic Initiatives
13.79. Laurent Pharmaceuticals Inc
13.79.1. Company Overview
13.79.2. Financial Performance
13.79.3. Product Portfolio
13.79.4. Strategic Initiatives
13.80. MannKind Corp
13.80.1. Company Overview
13.80.2. Financial Performance
13.80.3. Product Portfolio
13.80.4. Strategic Initiatives
13.81. Mariposa Health Ltd
13.81.1. Company Overview
13.81.2. Financial Performance
13.81.3. Product Portfolio
13.81.4. Strategic Initiatives
13.82. Microbion Corp
13.82.1. Company Overview
13.82.2. Financial Performance
13.82.3. Product Portfolio
13.82.4. Strategic Initiatives
13.83. Moderna Inc
13.83.1. Company Overview
13.83.2. Financial Performance
13.83.3. Product Portfolio
13.83.4. Strategic Initiatives
13.84. Mucokinetica Ltd
13.84.1. Company Overview
13.84.2. Financial Performance
13.84.3. Product Portfolio
13.84.4. Strategic Initiatives
13.85. Nanogenics Ltd
13.85.1. Company Overview
13.85.2. Financial Performance
13.85.3. Product Portfolio
13.85.4. Strategic Initiatives
13.86. Neupharma Srl
13.86.1. Company Overview
13.86.2. Financial Performance
13.86.3. Product Portfolio
13.86.4. Strategic Initiatives
13.87. New Amsterdam Sciences Inc
13.87.1. Company Overview
13.87.2. Financial Performance
13.87.3. Product Portfolio
13.87.4. Strategic Initiatives
13.88. Novabiotics Ltd
13.88.1. Company Overview
13.88.2. Financial Performance
13.88.3. Product Portfolio
13.88.4. Strategic Initiatives
13.89. Novoteris LLC
13.89.1. Company Overview
13.89.2. Financial Performance
13.89.3. Product Portfolio
13.89.4. Strategic Initiatives
13.90. Omnispirant Ltd
13.90.1. Company Overview
13.90.2. Financial Performance
13.90.3. Product Portfolio
13.90.4. Strategic Initiatives
13.91. Orphomed Inc
13.91.1. Company Overview
13.91.2. Financial Performance
13.91.3. Product Portfolio
13.91.4. Strategic Initiatives
13.92. OrPro Therapeutics Inc
13.92.1. Company Overview
13.92.2. Financial Performance
13.92.3. Product Portfolio
13.92.4. Strategic Initiatives
13.93. Oryn Therapeutics
13.93.1. Company Overview
13.93.2. Financial Performance
13.93.3. Product Portfolio
13.93.4. Strategic Initiatives
13.94. Paranta Biosciences Ltd
13.94.1. Company Overview
13.94.2. Financial Performance
13.94.3. Product Portfolio
13.94.4. Strategic Initiatives
13.95. Parion Sciences Inc
13.95.1. Company Overview
13.95.2. Financial Performance
13.95.3. Product Portfolio
13.95.4. Strategic Initiatives
13.96. Pharmaero ApS
13.96.1. Company Overview
13.96.2. Financial Performance
13.96.3. Product Portfolio
13.96.4. Strategic Initiatives
13.97. Pharmaxis Ltd
13.97.1. Company Overview
13.97.2. Financial Performance
13.97.3. Product Portfolio
13.97.4. Strategic Initiatives
13.98. PhaseBio Pharmaceuticals Inc
13.98.1. Company Overview
13.98.2. Financial Performance
13.98.3. Product Portfolio
13.98.4. Strategic Initiatives
13.99. Polyphor Ltd
13.99.1. Company Overview
13.99.2. Financial Performance
13.99.3. Product Portfolio
13.99.4. Strategic Initiatives
13.100. Progenra Inc
13.100.1. Company Overview
13.100.2. Financial Performance
13.100.3. Product Portfolio
13.100.4. Strategic Initiatives
13.101. ProQR Therapeutics NV
13.101.1. Company Overview
13.101.2. Financial Performance
13.101.3. Product Portfolio
13.101.4. Strategic Initiatives
13.102. Protalix BioTherapeutics Inc
13.102.1. Company Overview
13.102.2. Financial Performance
13.102.3. Product Portfolio
13.102.4. Strategic Initiatives
13.103. Proteostasis Therapeutics Inc
13.103.1. Company Overview
13.103.2. Financial Performance
13.103.3. Product Portfolio
13.103.4. Strategic Initiatives
13.104. Pulmatrix Inc
13.104.1. Company Overview
13.104.2. Financial Performance
13.104.3. Product Portfolio
13.104.4. Strategic Initiatives
13.105. Rare Partners Srl
13.105.1. Company Overview
13.105.2. Financial Performance
13.105.3. Product Portfolio
13.105.4. Strategic Initiatives
13.106. Recode Therapeutics Inc
13.106.1. Company Overview
13.106.2. Financial Performance
13.106.3. Product Portfolio
13.106.4. Strategic Initiatives
13.107. Renovion Inc
13.107.1. Company Overview
13.107.2. Financial Performance
13.107.3. Product Portfolio
13.107.4. Strategic Initiatives
13.108. Riptide Bioscience Inc
13.108.1. Company Overview
13.108.2. Financial Performance
13.108.3. Product Portfolio
13.108.4. Strategic Initiatives
13.109. Santhera Pharmaceuticals Holding AG
13.109.1. Company Overview
13.109.2. Financial Performance
13.109.3. Product Portfolio
13.109.4. Strategic Initiatives
13.110. SciBac Inc
13.110.1. Company Overview
13.110.2. Financial Performance
13.110.3. Product Portfolio
13.110.4. Strategic Initiatives
13.111. Sequoia Sciences Inc
13.111.1. Company Overview
13.111.2. Financial Performance
13.111.3. Product Portfolio
13.111.4. Strategic Initiatives
13.112. Silurian Pharmaceuticals Inc
13.112.1. Company Overview
13.112.2. Financial Performance
13.112.3. Product Portfolio
13.112.4. Strategic Initiatives
13.113. SolAeroMed Inc
13.113.1. Company Overview
13.113.2. Financial Performance
13.113.3. Product Portfolio
13.113.4. Strategic Initiatives
13.114. Specific Biologics Inc
13.114.1. Company Overview
13.114.2. Financial Performance
13.114.3. Product Portfolio
13.114.4. Strategic Initiatives
13.115. Spirovant Sciences Inc
13.115.1. Company Overview
13.115.2. Financial Performance
13.115.3. Product Portfolio
13.115.4. Strategic Initiatives
13.116. Spyryx Biosciences Inc
13.116.1. Company Overview
13.116.2. Financial Performance
13.116.3. Product Portfolio
13.116.4. Strategic Initiatives
13.117. Synedgen Inc
13.117.1. Company Overview
13.117.2. Financial Performance
13.117.3. Product Portfolio
13.117.4. Strategic Initiatives
13.118. Synovo GmbH
13.118.1. Company Overview
13.118.2. Financial Performance
13.118.3. Product Portfolio
13.118.4. Strategic Initiatives
13.119. Synspira LLC
13.119.1. Company Overview
13.119.2. Financial Performance
13.119.3. Product Portfolio
13.119.4. Strategic Initiatives
13.120. Takeda Pharmaceutical Co Ltd
13.120.1. Company Overview
13.120.2. Financial Performance
13.120.3. Product Portfolio
13.120.4. Strategic Initiatives
13.121. Tavanta Therapeutics Inc
13.121.1. Company Overview
13.121.2. Financial Performance
13.121.3. Product Portfolio
13.121.4. Strategic Initiatives
13.122. TGV-Inhalonix Inc
13.122.1. Company Overview
13.122.2. Financial Performance
13.122.3. Product Portfolio
13.122.4. Strategic Initiatives
13.123. Therapeutic Systems Research Laboratories Inc
13.123.1. Company Overview
13.123.2. Financial Performance
13.123.3. Product Portfolio
13.123.4. Strategic Initiatives
13.124. Translate Bio Inc
13.124.1. Company Overview
13.124.2. Financial Performance
13.124.3. Product Portfolio
13.124.4. Strategic Initiatives
13.125. Vast Therapeutics Inc
13.125.1. Company Overview
13.125.2. Financial Performance
13.125.3. Product Portfolio
13.125.4. Strategic Initiatives
13.126. Vectura Group Plc
13.126.1. Company Overview
13.126.2. Financial Performance
13.126.3. Product Portfolio
13.126.4. Strategic Initiatives
13.127. Vera Therapeutics Inc
13.127.1. Company Overview
13.127.2. Financial Performance
13.127.3. Product Portfolio
13.127.4. Strategic Initiatives
13.128. Verona Pharma Plc
13.128.1. Company Overview
13.128.2. Financial Performance
13.128.3. Product Portfolio
13.128.4. Strategic Initiatives
13.129. Vertex Pharmaceuticals Inc
13.129.1. Company Overview
13.129.2. Financial Performance
13.129.3. Product Portfolio
13.129.4. Strategic Initiatives
13.130. Vironika LLC
13.130.1. Company Overview
13.130.2. Financial Performance
13.130.3. Product Portfolio
13.130.4. Strategic Initiatives
13.131. Zambon Co SpA
13.131.1. Company Overview
13.131.2. Financial Performance
13.131.3. Product Portfolio
13.131.4. Strategic Initiatives
13.132. Zata Pharmaceuticals Inc
13.132.1. Company Overview
13.132.2. Financial Performance
13.132.3. Product Portfolio
13.132.4. Strategic Initiatives
13.133. Zikani Therapeutics Inc
13.133.1. Company Overview
13.133.2. Financial Performance
13.133.3. Product Portfolio
13.133.4. Strategic Initiatives